FDA tied AI-assisted drafting directly to established Quality Unit accountability under 21 CFR 211.22(c) for approving/rejecting specifications and procedures affecting identity, strength, quality, ...
Phase 2 data support soluble guanylate cyclase activation using nurandociguat as a potential adjunctive treatment in patients with chronic kidney disease already receiving current standard of care ...
In Ghatal, they have long given up on a master solution to their decadal monsoon problem. Instead, each family seems to have ...
Inaugurating the conference session of the Pharmac South Expo in Chennai recently, the DCGI unequivocally clarified to the pharmaceutical industry that the government remains resolute in the ...
Hone Health reports that 50% of peptide users mistakenly believe they take FDA-approved compounds, highlighting risks of ...
The FDA Manufacturing PreCheck Program is a voluntary pilot initiative authorized under Executive Order 14293, designed to ...
Approval from Loewenstein Medical Center enables patient identification for Company's planned first-in-human spinal cord injury study TEL AVIV, Israel, July 9, 2026 ...
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the commercial launch of its first medical cannabis product ...
Sustainability and single-use bioprocessing disposables are the most consequential operational challenges facing biomanufacturing today. Single-use systems transformed contamination control and ...
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...
Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical ManufacturingAGOURA HILLS, ...
Several ASX healthcare companies are tackling neurodegenerative diseases where effective treatments remain limited.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results